-
Beijing Launches HIV Precision Medicine Standardization Project
•
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project, led by the National Center for Infectious Diseases (NCID) and the China National Health Association (CNHA) and sponsored by Gilead Sciences, aims to enhance the quality of HIV outpatient services in hospitals. The initiative seeks…
-
Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive licensing deal with compatriot firm Jiangsu Carephar Pharmaceutical Co., Ltd to develop H008 globally, including its oral preparation and injection forms, and covering all plausible indications. Agreement Details and Rights AllocationUnder the agreement, Carephar will…
-
Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline
•
China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by Proxima Ventures, with proceeds directed towards clinical studies, new adeno-associated virus (AAV) carrier design, pilot-scale production line construction, and expansion of the gene therapy…
-
Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced that it has received Category III medical device approval from the National Medical Products Administration (NMPA) for its in-house developed peripheral cutting balloon. This approval marks a significant milestone for the company in expanding its…
-
Lepu Medtech Prices GDR Offering for International Expansion
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced its offering of 11,910,286 global depository receipts (GDRs) to the SWX Swiss Exchange (SWX) at USD 12.31 to USD 12.68 per share. The proceeds from the offering are expected to range from USD 148.8 million…
-
Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D
•
China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money in a Series A financing round. The investment was led by Huaying Capital from Zhongshan Torch Development Zone and Chengdu Shengrong Longke Technology Co., Ltd. The funding will support the company’s ongoing research and development…
-
NHSA Launches Expert Review for 2025 NRDL Update in China
•
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert review process for this year’s National Reimbursement Drug List (NRDL) update. The three-day event, held in Beidaihe, Qinhuangdao, Hebei province, will conclude on September 22. This process is a crucial step in determining which drugs…
-
Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment
•
South Korea’s Daehwa Pharmaceutical (KOSDAQ: 067080) has announced the filing of a New Drug Application (NDA) in China for Liporaxel/RMX3001, its innovative oral paclitaxel formulation. The application seeks approval for Liporaxel as a secondary treatment option for patients with advanced gastric cancer. Liporaxel: An Innovative Oral FormulationLiporaxel is an oral…
